for the maintenance treatment of copd

dual bronchodilation,

down to a science

Not indicated for the relief of acute bronchospasm or for the treatment of asthma.

Adverse reactions with BEVESPI AEROSPHERE with a ≥2% incidence and more common than placebo were urinary tract infection and cough.1


Improved lung function including predose FEV1 and peak FEV1 at 24 weeks1,2

In a separate study vs placebo, improvement in peak inspiratory capacity at Day 293†

*Defined as superior improvements in lung function relative to its individual components and placebo in two 24-week pivotal trials (n=3699).

In a separate Phase IIIb trial (n=35), there was a significant mean improvement in primary endpoint FEV1 AUC0-24 on Day 29 vs placebo. Peak inspiratory capacity after the evening dose on Day 29 was a secondary endpoint. Similar results seen in a second Phase IIIb trial (n=75).